New Studies Confirm MiSight® 1 day Retinal Defocus Performance and Accommodative Behavior in High Myopes

Tuesday, October 25 2022 | 16 h 29 min | News

New research from CooperVision explores accommodative behavior and retinal defocus performance of MiSight^® 1 day contact lenses in eyes with higher levels of myopia. Findings demonstrated that the dual focus optical design was able to introduce myopic defocus at all viewing distances.

With newly expanded parameters (up to -7.00 in Canada and the United States), Eye Care Professionals can confidently treat more age-appropriate children impacted by the growing prevalence and severity of myopia.

Introduction of myopic retinal defocus in highly myopic eyes using a dual focus myopia control contact lens (Gantes et al.) and Accommodative behavior and retinal defocus in highly myopic eyes fit with a dual focus myopia control contact lens (Meyer et al.) are being presented at the 2022 American Academy of Optometry annual meeting this week.

These scientific works examine highly myopic eyes (–6.50 to –10.00D, mean ± SD: –8.00±1.02D) fit with single-vision and MiSight^® 1 day lenses, revealing that eyes accommodated similarly in both cases. Small accommodative leads at distance did not prevent +2.00D myopic defocus in the MiSight^® 1 day treatment optics from being imposed on the retina. Researchers also found that higher powers did not prevent the lens from reducing hyperopic retinal defocus across the central 40 degrees of the horizontal retina.

“CooperVision has invested decades into myopia research and development to provide evidence-based interventions for children with this disease,” said Paul Chamberlain, BSc (Hons), Senior Director of Research Programs, CooperVision. “Combining these latest findings with our extensive and rigorous body of existing work helps eye care professionals take on myopia with more confidence, reaching even more children around the world.”

Chamberlain will present MiSight^® 1 day myopia control therapy assessment in fast and slow progressors, a paper that describes the proportional treatment effect that allows faster-progressing children to receive the maximum myopia control benefit. The analysis is based on data gathered during years four through six of the international MiSight^® 1 day clinical trial, when study participants were aged 11 to 15 years old.

The Academy designated this work as one of the ten most newsworthy developments at the entire meeting. Chamberlain will preview the findings during the Academy’s global virtual press conference this evening.

Supporting CooperVision’s comprehensive myopia management portfolio, Efficacy of Fitting Ortho-K Contact Lenses Utilizing a Mobile Fitting Application (Voltz et al) demonstrates how lens parameters recommended by the Paragon CRT^® Lens Calculator are in close alignment with those determined diagnostically, helping to save chair time.

The company also funded Preliminary Modification and Adaptation of a Quality of Vision Questionnaire for Children (Postnikoff et al.), research surrounding the modernization of a quality of vision questionnaire to make it suitable for optical myopia control interventions with children.

These studies join multiple company-led and funded scientific papers and posters that will be presented at the American Academy of Optometry meeting, which takes place from October 26-29 in San Diego, California.

Click HERE for the full press release.